Clinical Trial Diversity: User Fee Bill Wants FDA’s Assessment Of Whether It Needs More Authority

HHS is to evaluate the need for FDA authority to mandate postapproval studies or postmarket surveillance if sponsors do not meet diversity enrollment goals. By contrast, the DEPICT Act would have given the agency the authority to do so.